AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
The 50 most promising Israeli startups - 2024
3
Blackstone acquires Israel’s Priority Software at an $800 million valuation
4
Moritz code: Inside the mind of the best VC investor ever
5
Israel’s Tictuk acquired by Yum! Brands, owner of KFC, Pizza Hut, and Taco Bell
More news

Teva

20 stories about Teva
מטה חברת טבע תרופות

Judge Rejects Teva’s Request to Be Tried Separately in U.S. Opioid Case, Report Says

13.10.19|CTech
Teva made a last minute attempt to be tried separately in opioid abuse damages case set to be held on October 21 in federal court in Cleveland, Ohio
מטה חברת טבע תרופות

Teva Part of Consortium Looking to Participate in Purdue Pharma's Bankruptcy, Report Says

02.10.19|CTech
Five of the drugmakers currently battling opioid abuse damages lawsuits in the U.S. are looking to achieve a global settlement through Purdue's bankruptcy case, the Wall Street Journal reported Monday
רון מירון מנכ"ל חברת אייסיקיור

Cannabis Company InnoCan Lists on the Canadian Securities Exchange

26.09.19|Tzally Greenberg
The Israel-based company listed 4% of its shares and raised $1.5 million at a $12.08 million company valuation
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
מטה חברת טבע תרופות

Teva Crashes Following Purdue Pharma $10-$12 Billion Settlement Reports

28.08.19|Lilach Baumer
Teva, like many other opioid manufacturers operating in the U.S., will be facing multiple opioid abuse-related lawsuits at a trial set to start in October at an Ohio federal court
אתר טבע כפר סבא

Teva Faces New Opioid-Related Lawsuit in West Virginia

25.08.19|Hezi Sternlicht
The lawsuit seems to be unrelated to the trial set to start against Teva and other opioid manufacturers in October in Ohio federal court
מטה חברת טבע תרופות

Teva Jumps on NYSE on a Bit of Good News

21.08.19|Hezi Sternlicht
An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
default image

Senior Teva R&D Executive Joins Cannabis Company Cannassure

18.08.19|Tzally Greenberg
Yafit Stark was responsible for Teva’s clinical development program during the development of flagship drug Copaxone
מטה חברת טבע תרופות

Despite Losses, Teva Pays Employee Bonuses for 2018

13.08.19|Hezi Sternlicht
Though Teva ended 2018 with a net loss of over $2.45 billion, the company awarded its employees with bonuses worth $390 million for the fiscal year’s results
מפעל תרופות טבע

Credit Line and Bonds: Teva's Financial Catch

12.08.19|Uri Tal-Tene
At first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beat Analysts’ Consensus, But Its Big Battles Are Still Up Ahead

08.08.19|Sophie Shulman
Teva ends the second quarter of 2019 down a CFO, with negative cash flow and the threat of lawsuits that could cost billions. In his call with analysts, CEO Kare Schultz hinted at the possibility of future layoffs, but Teva still handed out $240 million worth of annual bonuses to senior executives
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beats Analysts on Second Quarter Operating Income, Revenues

07.08.19|CTech
The company also announced chief financial officer Michael McClellan will be stepping down after two years for personal reasons related to family
קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
אתר טבע כפר סבא

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

30.07.19|Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
אתר טבע כפר סבא

Former Execs, Directors, to Pay Teva $50 Million for Part in Bribery Damages

25.07.19|Tomer Ganon
A recently reached settlement will see the Israeli drugmaker receive compensation for the fines it paid U.S. and Israeli authorities after being charged with conspiracy to violate the anti-bribery provisions of the Foreign Corrupt Practices Act in 2016
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Where is Kåre Schultz?

17.07.19|Sophie Shulman
The Danish CEO was drafted to save Teva straight off the successful turnaround of pharma company Lundbeck. Since then, the Israeli company’s market cap dropped by 66%, but Schultz has stayed mum
אתר טבע כפר סבא

Teva Falls on Pre-Market Trading After Morgan Stanley Downgrade

15.07.19|CTech
Teva recently reached an $85 million settlement with the State of Oklahoma regarding its alleged role in the state’s opioid crisis, but is still facing many more claims
אתר טבע כפר סבא

Court Approves One Teva Opioid Settlement, Many More to Come

25.06.19|Hezi Sternlicht
The settlement will see Teva will pay Oklahoma a one-time payment of $85 million to settle claims that it had played a role in exacerbating the U.S. opioid use epidemic there
אתר טבע כפר סבא

Fitch Downgrades Teva, Keeps Outlook at Negative

10.06.19|Hezi Sternlicht
Fitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
Previous ArticlesMore Articles